RESUMEN
Drug shortages threaten patients' access to medications and are associated with adverse health outcomes and increased costs. Drug shortages disproportionately occur among generic drugs of limited profitability, most notably drugs administered by injection. In this perspective, we discuss how reimbursement and purchasing practices that were meant to create an efficient marketplace for generics have generated strong price pressure that threatens profitability in certain markets. We further explain how, faced with limited profitability, manufacturers lack incentives to invest in resilient supply chains, and in some cases, engage in cost-containment strategies or decide to exit the market, ultimately contributing to shortages. We propose the development and implementation of value-based reimbursement to provide needed incentives for drug purchasers and manufacturers to establish a more reliable supply chain as part of the policy solution to reduce the number and extent of drug shortages. This reimbursement model would necessitate the development of a rating system that measures supply chain resilience and maturity for each generic product. This rating would then be applied as a value-based modifier to reimbursement rates for generic products. The proposed model would result in higher reimbursement rates for generic products from more dependable supply chains, generating incentives for manufacturers to invest in supply chain resiliency. We propose the application of this reimbursement system originally in Medicare given Congressional interest on reforming Medicare payment to prevent drug shortages.
Asunto(s)
Industria Farmacéutica , Medicamentos Genéricos , Estados Unidos , Medicamentos Genéricos/economía , Medicamentos Genéricos/provisión & distribución , Humanos , Industria Farmacéutica/economía , Costos de los Medicamentos , Control de Costos , Preparaciones Farmacéuticas/provisión & distribución , Preparaciones Farmacéuticas/economía , Compra Basada en Calidad , Mecanismo de ReembolsoRESUMEN
This study evaluates the characteristics of generic active pharmaceutical ingredients (APIs) used to manufacture drugs with shortages in the US and facilities producing APIs worldwide.
Asunto(s)
Medicamentos a Granel , Industria Farmacéutica , Medicamentos Genéricos , Medicamentos a Granel/economía , Medicamentos a Granel/provisión & distribución , Industria Farmacéutica/economía , Industria Farmacéutica/estadística & datos numéricos , Industria Farmacéutica/tendencias , Medicamentos Genéricos/economía , Medicamentos Genéricos/provisión & distribución , Estados Unidos , InternacionalidadRESUMEN
BACKGROUND: Generic drug manufacturing has shifted away from the U.S. in the last few decades. The medication supply chain, from manufacturers to resellers, has become increasingly globalized and complex. This has led to bottlenecks in their manufacture resulting in medication shortages. Review of this process as it pertains to antiseizure medications (ASM) shows gaps in our comprehension of its complexities. Understanding these processes will be essential for preventing medication shortages. OBJECTIVES: The aim of this research is to examine the generic ASM supply with an emphasis on production, labeling, and repackaging. METHODS: Data from the United States Food and Drug Administration (FDA) and the National Library of Medicine (NLM) website DailyMed was used to evaluate supply chain details to gather information on antiseizure medication formulations, manufacturing locations, and labeling. RESULTS: Out of 3142 ASM-related active National Drug Code (NDC-9) codes, 2663 NDC-9 codes with Abbreviated New Drug Application (ANDA) status were included in the analysis. Most (94.8 %) were enteral, with only 5.2 % being parenteral (intravenous and intramuscular route). We identified the manufacturing country for 82 % of these codes, corresponding to 306 unique ANDA numbers. 119 manufacturing sites in 12 countries produce generic ASM Finished Dosage Forms (FDF): 103 for enteral and 21 for parenteral. India is the main producer of enteral ASM FDFs with 49 sites, followed by the US with 36. Regarding parenteral formulation, five countries had 21 unique manufacturing locations. 42 % of the 103 enteral ASM FDFs manufacturing sites produced multiple ASM FDFs, with one facility making eight distinct ASMs. 34.4 % of facilities were associated with over 3 ANDAs, and 15.1 % with more than 5. 22.7 % of ANDAs lacked a manufacturing facility identifier. Repackaged ASM FDFs constituted 48 % of NDC-9 s. Gabapentin and pregabalin were the most common oral ASMs. CONCLUSIONS: India is the major source for generic ASM FDFs manufacturing, leading to concerns about overall supply dependency on that country. There is a paucity of facilities for the global supply of parenteral ASM FDFs. There is missing data for many NDC-9 codes emphasizing urgency for transparency in the supply chain.
Asunto(s)
Anticonvulsivantes , Medicamentos Genéricos , Humanos , Estados Unidos , Medicamentos Genéricos/provisión & distribución , Anticonvulsivantes/provisión & distribución , Anticonvulsivantes/uso terapéutico , United States Food and Drug Administration , Bases de Datos Factuales , National Library of Medicine (U.S.) , Industria FarmacéuticaRESUMEN
This Viewpoint discusses how limited-supply agreements (introduction of generic products in reduced volumes) might thwart efforts to negotiate lower prices on prescription drugs in the US.
Asunto(s)
Costos de los Medicamentos , Industria Farmacéutica , Medicare , Negociación , Preparaciones Farmacéuticas , Anciano , Humanos , Costos de los Medicamentos/estadística & datos numéricos , Medicamentos Genéricos/economía , Medicamentos Genéricos/provisión & distribución , Medicare/economía , Medicare/legislación & jurisprudencia , Medicare/estadística & datos numéricos , Estados Unidos/epidemiología , Industria Farmacéutica/economía , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/estadística & datos numéricos , Comercio/economía , Comercio/legislación & jurisprudencia , Comercio/estadística & datos numéricos , Preparaciones Farmacéuticas/economía , Preparaciones Farmacéuticas/provisión & distribuciónRESUMEN
INTRODUCTION: There is concern around non-prescribed benzodiazepine use, particularly with increasing detections of counterfeit products containing high-risk novel compounds. The aims of this study were to investigate how and which non-prescribed benzodiazepines are being sourced; forms, appearance and packaging; and awareness of risks associated with non-prescribed benzodiazepines. METHODS: Data were collected from a sample of Australians who inject drugs or use ecstasy and/or other illicit stimulants on a monthly or more frequent basis, and who reported past 6-month use of non-prescribed benzodiazepines (n = 235 and n = 250, respectively). Data were collected on source, diversion from a known/trusted prescription, product name and aesthetic characteristics for the last non-prescribed benzodiazepine obtained. RESULTS: Amongst participants who injected drugs, 71% reported that their last non-prescribed benzodiazepines were diverted from a known/trusted prescription, compared to 59% of participants who used ecstasy/other stimulants. Sourcing via cryptomarkets was rare. Across both samples, the majority reported last obtaining substances sold/marketed as diazepam or alprazolam. Participants sourcing via non-diverted means were twice as likely to obtain alprazolam. Known sourcing of novel compounds was rare. Amongst participants who used ecstasy/other stimulants, 36% reported confidence in the content/dose of non-prescribed benzodiazepines even when the source is unknown. DISCUSSION AND CONCLUSIONS: Most participants obtained substances sold as classic/registered benzodiazepines, mostly via diverted prescriptions, with a substantial minority potentially unaware of counterfeits circulating. While diverted use undeniably presents risks, tightening of prescriptions in Australia could inadvertently lead to greater supply of novel benzodiazepines as seen internationally, reinforcing prioritisation of demand and harm reduction strategies.
Asunto(s)
Benzodiazepinas , Sustancias Controladas , Medicamentos Falsificados , Drogas Ilícitas , Mercadotecnía , Daño del Paciente , Conocimiento de la Medicación por el Paciente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Alprazolam/provisión & distribución , Australia , Benzodiazepinas/economía , Benzodiazepinas/normas , Benzodiazepinas/provisión & distribución , Seguridad Química , Seguridad de Productos para el Consumidor , Sustancias Controladas/economía , Sustancias Controladas/normas , Sustancias Controladas/provisión & distribución , Medicamentos Falsificados/economía , Medicamentos Falsificados/provisión & distribución , Diazepam/provisión & distribución , Abuso de Medicamentos/prevención & control , Abuso de Medicamentos/estadística & datos numéricos , Embalaje de Medicamentos , Medicamentos Genéricos/química , Medicamentos Genéricos/normas , Medicamentos Genéricos/provisión & distribución , Drogas Ilícitas/química , Drogas Ilícitas/normas , Drogas Ilícitas/provisión & distribución , Entrevistas como Asunto , Mercadotecnía/estadística & datos numéricos , N-Metil-3,4-metilenodioxianfetamina , Daño del Paciente/prevención & control , Daño del Paciente/estadística & datos numéricos , Conocimiento de la Medicación por el Paciente/estadística & datos numéricos , Programas de Monitoreo de Medicamentos Recetados , Riesgo , Autoinforme , IncertidumbreRESUMEN
BACKGROUND: Z-drugs are nonbenzodiazepine hypnotics used for sleep initiation and maintenance; these drugs increase the risk of fall-related injuries in older adults. The American Geriatrics Society's Beers criteria classifies Z-drugs as high-risk and strongly recommends avoiding prescribing Z-drugs to older adults due to adverse effects. The study objectives were to determine the prevalence of Z-drug prescribing among Medicare Part D patients and identify state or specialty-dependent prescribing differences. This study also aimed to determine prescribing patterns of Z-drugs to Medicare patients. METHODS: Z-drug prescription data was extracted from the Centers for Medicare and Medicaid Services State Drug Utilization Data for 2018. For all 50 states, the number of prescriptions per 100 Medicare enrollees and days-supply per prescription was determined. The percentage of total prescriptions prescribed by each specialty and the average number of prescriptions per provider within each specialty was also determined. RESULTS: Zolpidem was the most prescribed Z-drug (95.0%). Prescriptions per 100 enrollees were significantly high in Utah (28.2) and Arkansas (26.7) and significantly low in Hawaii (9.3) relative to the national average (17.5). Family medicine (32.1%), internal medicine (31.4%), and psychiatry (11.7%) made up the largest percentages of total prescriptions. The number of prescriptions per provider was significantly high among psychiatrists. DISCUSSION: Contrary to the Beers criteria, Z-drugs are prescribed to older adults at high rates.
Asunto(s)
Prescripciones de Medicamentos , Medicare Part D , Zolpidem , Humanos , Masculino , Femenino , Anciano , Estados Unidos/epidemiología , Zolpidem/uso terapéutico , Medicamentos Genéricos/provisión & distribución , Prescripciones de Medicamentos/estadística & datos numéricosRESUMEN
BACKGROUND: The introduction of medicine pricing policies in South Africa (SA) in the form of single exit pricing (SEP) provided a mechanism to improve medicine price transparency and reduce the medicine price and inflation. However, regulation of medicine prices may have further unforeseen effects on the availability of medicine. This research presents the impact of SEP on discontinuation of medicine products on the private healthcare market in SA. OBJECTIVES: To evaluate the impact of SEP legislation on the availability of medicines in the SA private health sector in terms of withdrawal of medicines from the market. METHODS: A descriptive, quantitative analysis of all registered medicines on the SA market by stock-keeping units (SKUs) was done to establish medicine products that were withdrawn from the market by SKUs during a 14-year period (2001 - 2014). RESULTS: A total of 152 manufacturers discontinued 3 691 SKUs between 2001 and 2014. The mean number of discontinuations per generic manufacturer was 22.34 (standard deviation (SD) 58.11), while innovator manufacturers discontinued a mean of 27.61 (41.89). The largest number of SKUs were commercially withdrawn in 2002 (n=603), followed by discontinuations in 2003 (n=463) and 2004 (n=407). There was a negative correlation between number of discontinued SKUs per year and SEP increase (Pearson's correlation coefficient r â0.414; p=0.14). The results showed that SEP and a transparent pricing policy may have had an impact on SKU withdrawal from the market prior to SEP implementation. CONCLUSIONS: The result of reduced product availability on the market and its impact on the cost and quality of healthcare to the patient need to be regularly monitored and evaluated to ascertain if direct price regulations achieve the intended outcomes. Other intended or unintended effects on pharmaceutical market dynamics should also be evaluated.
Asunto(s)
Costos de los Medicamentos , Medicamentos Genéricos/economía , Sector de Atención de Salud/economía , Preparaciones Farmacéuticas/economía , Costos y Análisis de Costo , Atención a la Salud/economía , Medicamentos Genéricos/provisión & distribución , Humanos , Preparaciones Farmacéuticas/provisión & distribución , Sector Privado/economía , Recall y Retirada del Producto , SudáfricaRESUMEN
Poor control of cardiovascular disease accounts for a substantial proportion of the disease burden in developing countries, but often essential anticoagulant medicines for preventing strokes and embolisms are not widely available. In 2019, direct oral anticoagulants were added to the World Health Organization's WHO Model list of essential medicines. The aims of this paper are to summarize the benefits of direct oral anticoagulants for patients with cardiovascular disease and to discuss ways of increasing their usage internationally. Although the cost of direct oral anticoagulants has provoked debate, the affordability of introducing these drugs into clinical practice could be increased by: price negotiation; pooled procurement; competitive tendering; the use of patent pools; and expanded use of generics. In 2017, only 14 of 137 countries that had adopted national essential medicines lists included a direct oral anticoagulant on their lists. This number could increase rapidly if problems with availability and affordability can be tackled. Once the types of patient likely to benefit from direct oral anticoagulants have been clearly defined in clinical practice guidelines, coverage can be more accurately determined and associated costs can be better managed. Government action is required to ensure that direct oral anticoagulants are covered by national budgets because the absence of reimbursement remains an impediment to achieving universal coverage. Tackling cardiovascular disease with the aid of direct oral anticoagulants is an essential component of efforts to achieve the World Health Organization's target of reducing premature deaths due to noncommunicable disease by 25% by 2025.
L'absence de lutte efficace contre les maladies cardiovasculaires contribue grandement à la charge de morbidité pesant sur les pays en développement. Pourtant, les anticoagulants essentiels permettant d'éviter les accidents vasculaires cérébraux et les embolies sont souvent difficiles à obtenir. En 2019, les anticoagulants oraux directs ont été ajoutés à la Liste modèle des médicaments essentiels publiée par l'Organisation mondiale de la Santé. Le présent document vise à résumer les avantages des anticoagulants oraux directs pour les patients souffrant d'une maladie cardiovasculaire, et à évoquer les moyens d'encourager leur utilisation au niveau international. Bien que le coût des anticoagulants oraux directs ait fait débat, intégrer ces médicaments dans la pratique clinique les rendrait plus abordables grâce à diverses méthodes: négociation des prix; achats groupés; appels d'offres concurrentiels; communautés de brevets; et recours accru aux alternatives génériques. En 2017, seulement 14 des 137 pays ayant adopté des listes nationales de médicaments essentiels y avaient inclus des anticoagulants oraux directs. Ce chiffre pourrait augmenter rapidement si les problèmes de disponibilité et d'accessibilité peuvent être résolus. Dès que les profils des patients susceptibles d'être traités par des anticoagulants oraux directs sont clairement établis dans les directives de pratique clinique, la couverture peut être définie avec plus de précision et les dépenses correspondantes, mieux gérées. Les gouvernements doivent s'assurer que ces médicaments sont bien pris en compte dans les budgets nationaux, car l'absence de remboursement demeure un obstacle à la couverture maladie universelle. La lutte contre les maladies cardiovasculaires à l'aide des anticoagulants oraux directs est un élément essentiel des efforts destinés à atteindre l'objectif de l'OMS: faire baisser de 25% d'ici 2025 les décès prématurés dus aux maladies non transmissibles de 25% d'ici 2025.
El mal control de las enfermedades cardiovasculares representa una proporción importante de la carga de enfermedades en los países en desarrollo, y a menudo los medicamentos anticoagulantes esenciales para prevenir los accidentes cerebrovasculares y las embolias no son fácilmente accesibles. En 2019, los anticoagulantes orales directos se añadieron a la lista modelo de medicamentos esenciales de la Organización Mundial de la Salud. Los objetivos del presente artículo son resumir los beneficios de los anticoagulantes orales directos para los pacientes con enfermedades cardiovasculares y discutir las formas de aumentar su uso a nivel internacional. Aunque el coste de los anticoagulantes orales directos ha suscitado debate, la asequibilidad de introducir estos medicamentos en la práctica clínica podría aumentarse al: negociar precios; hacer adquisiciones conjuntas; hacer licitaciones competitivas; utilizar consorcios de patentes; y ampliar el uso de genéricos. En 2017, solo 14 de los 137 países que habían adoptado listas nacionales de medicamentos esenciales incluían un anticoagulante oral directo en sus listas. Este número podría aumentar rápidamente si se pueden abordar los problemas de disponibilidad y asequibilidad. Cuando los tipos de pacientes que pueden beneficiarse de los anticoagulantes orales directos se hayan definido claramente en las directrices de la práctica clínica, la cobertura podrá determinarse con mayor precisión y los costes asociados podrán gestionarse mejor. Es necesario que los gobiernos actúen para garantizar que los anticoagulantes orales directos estén cubiertos por los presupuestos nacionales, ya que la ausencia de reembolso sigue siendo un impedimento para lograr la cobertura universal. La lucha contra las enfermedades cardiovasculares con la ayuda de los anticoagulantes orales directos es un componente esencial de los esfuerzos por alcanzar el objetivo de la OMS de reducir las muertes prematuras debidas a enfermedades no transmisibles en un 25 % para 2025.
Asunto(s)
Anticoagulantes/economía , Costos de los Medicamentos , Medicamentos Esenciales/provisión & distribución , Medicamentos Genéricos/provisión & distribución , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Anticoagulantes/administración & dosificación , Anticoagulantes/uso terapéutico , Costos y Análisis de Costo , Medicamentos Esenciales/economía , Medicamentos Genéricos/economía , Costos de la Atención en Salud , HumanosRESUMEN
INTRODUCTION: many hypertensive patients require two or more anti-hypertensive drugs, but in low- and middle-income countries there may be challenges with medication access or affordability. The objective of this study was to determine accessibility and affordability of anti-hypertensive medicines and their association with blood pressure (BP) control among hypertensive patients attending the Korle-Bu teaching hospital (KBTH) polyclinic. METHODS: a cross-sectional study was conducted among 310 systematically sampled hypertensive patients attending the KBTH Polyclinic in Ghana. A structured questionnaire was used to obtain data on patient demographics and clinical characteristics, prices, availability and mode of payment of generic anti-hypertensive medicines. RESULTS: fifty-nine patients (19.4%) made out-of-pocket payments. At the private pharmacy and hospital, 123 (40.5%) and 77 patients (25.3%) respectively could not afford four anti-hypertensive medicines. Medicines availability at KBTH was 60%. Continuous access to BP drugs at KBTH was 14.8%. Overall access was 74.9% (SD ± 41.3). Out-of-pocket affordability of the medicines was positively correlated with BP control (R=0.12, p=0.037). Obtaining medicines via health insurance only was more likely to result in BP control than making any out-of-pocket payments (OR= 2.185; 95% CI, 1.215 - 3.927). Access at KBTH was more likely to result in BP control (OR=1.642; 95% C.I, 0.843 - 3.201). CONCLUSION: there were access challenges although most patients obtained BP medication free. Out-of-pocket affordability is a challenge for some hypertensive patients. Access to affordable BP medication can improve BP control. These findings provide an impetus for urgently evaluating access to affordable anti-hypertensive medicines in other hospitals in Ghana.
Asunto(s)
Antihipertensivos/administración & dosificación , Medicamentos Genéricos/administración & dosificación , Accesibilidad a los Servicios de Salud/economía , Hipertensión/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antihipertensivos/economía , Antihipertensivos/provisión & distribución , Presión Sanguínea/efectos de los fármacos , Costos y Análisis de Costo , Estudios Transversales , Medicamentos Genéricos/economía , Medicamentos Genéricos/provisión & distribución , Femenino , Ghana , Gastos en Salud/estadística & datos numéricos , Hospitales de Enseñanza , Humanos , Hipertensión/economía , Seguro de Salud/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Encuestas y Cuestionarios , Adulto JovenRESUMEN
Policy Points Much concern about generic drug markets has emerged in recent policy debates. Important changes in regulations, the structure of purchasing, and the length of the drug supply chain have affected generic drug markets. Effective price competition remains the rule in generic markets for large-selling drugs. Smaller markets and those for injectable products often have less price competition and are more susceptible to supply disruptions. CONTEXT: The image of generic drugs as a commodity sold in competitive markets is an oversimplification, as evidenced by increasing accounts of price spikes, sustained high price-cost margins, and market disruptions. The mismatch between the canonical economic model of generic drug markets and reality motivated our empirical project. METHODS: To explore recent changes in those factors impacting the supply and demand for generic drugs, we studied, from a variety of sources, the data on price, competition, supply disruptions and recalls, changes to the supply chain, and buy-side concentration. We examined quarterly data through 2018 for a cohort of 77 molecules that lost patent protection during the so-called patent cliff between 2010 and 2013. FINDINGS: On the supply side, we found that for large-market oral solids, generic entry and price declines were consistent with past studies showing a significant number of market entrants and substantial reductions in the average price of a molecule. In smaller markets for oral solids and injectable products, we observed fewer entrants, higher rates of exit, smaller price reductions, and, in some cases, considerable price instability. The number of reported shortages increased across all generic market types over time, with the rate of shortage increases especially pronounced in markets for injectable products. The number of product recalls also rose over our study period. Although we did not estimate causal effects, we did find several changes in the market environment for generic drugs that may contribute to these phenomena. The demand side for generics has become more concentrated. Supply chains rely more on producers outside the United States (particularly from China and India). Contracting practices have undergone changes that may inhibit competition in product supply. FDA regulatory scruitiny has increased. CONCLUSIONS: Competition in generic drug markets varies widely by market size and product form. Recent changes in demand-side market structure imply more downward pressure on prices stemming from buy-side concentration. The FDA's greater regulatory oversight puts upward pressure on costs, and the lengthening of the supply chain increases production uncertainty for producers. Demand and supply-side changes point to further market instabilities across all generic markets due to producers' changing economic position.
Asunto(s)
Industria Farmacéutica/economía , Medicamentos Genéricos/economía , Medicamentos Genéricos/provisión & distribución , Competencia Económica , Costos y Análisis de Costo , Política de Salud , Humanos , Estados Unidos , United States Food and Drug AdministrationRESUMEN
The COVID-19 pandemic has revealed the vulnerability of the US generic drug supply chain to foreign production. Many policies have been proposed to mitigate this vulnerability. In this article, we argue that nonprofit drug manufacturers have the potential to make important contributions.
Asunto(s)
Industria Farmacéutica/economía , Medicamentos Genéricos/provisión & distribución , Organizaciones sin Fines de Lucro/economía , Medicamentos bajo Prescripción/provisión & distribución , Legislación como Asunto , Estados UnidosRESUMEN
BACKGROUND: Shortages of opioid analgesics are increasingly common, interfere with patient care and increase healthcare cost. This study characterized the incidence of shortages of opioid analgesics in the period 2015-2019 and evaluated potential predictors to forecast the risk of shortages. METHODS: This was an observational retrospective study using the US Food and Drug Administration (FDA) drug shortages data. All FDA approved opioids were included in the study. Opioid analgesics were identified using the FDA National Drug Codes (NDC) and classified according to the Drug Enforcement Administration (DEA) schedule. We conducted Least Absolute Shrinkage and Selection Operator logistic regression analysis to assess direction of the association between risk of shortage and potential predictors. We used multivariable penalized logistic regression analysis to model predictors of shortages. We split the dataset into training and validation sets to evaluate the performance of the model. FINDINGS: The FDA approved 8,207 unique NDCs for opioid analgesics; 3,017 (36.8%) were in the market as of April 30, 2019 and 91(3.0%) of them were listed as in shortage by the FDA. All NDCs in shortage were schedule II opioids; 86 (94.5%) were injectable and 84 (92.3%) generics. There were 418 companies with at least one opioid NDC listed by the FDA. Three companies accounted for more than 4 in 5 of the schedule II active injectable opioids. For each unit increase in the number of prior instances of shortages of a company, the likelihood of an NDC shortage for that company increased by 3.4%. For each unit increase in number of NDCs marketed by a company, the odds of an NDC shortage for that company decreased by 1%. CONCLUSIONS: In the period 2015-2019, shortages of opioid analgesics disproportionally impacted schedule II and injectable opioids. The risk of shortage of opioid analgesics significantly increased with the incidence of previous instances of shortages of a manufacturing company and decreased with the number of NDCs marketed by a company. The characteristics of the manufacturing company, rather than the number of companies, might be the missing piece to the complex puzzle of drug shortages in the US.
Asunto(s)
Analgésicos Opioides/provisión & distribución , Industria Farmacéutica/estadística & datos numéricos , Analgésicos Opioides/economía , Área Bajo la Curva , Industria Farmacéutica/economía , Medicamentos Genéricos/provisión & distribución , Humanos , Modelos Logísticos , Oportunidad Relativa , Curva ROC , Estudios Retrospectivos , Estados Unidos , United States Food and Drug AdministrationAsunto(s)
Tecnología Disruptiva/métodos , Aprobación de Drogas/legislación & jurisprudencia , Desarrollo de Medicamentos/legislación & jurisprudencia , Medicamentos Genéricos/normas , Administración Tópica , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Productos Biológicos/uso terapéutico , Desarrollo de Medicamentos/métodos , Medicamentos Genéricos/provisión & distribución , Síndromes de Ojo Seco/tratamiento farmacológico , Equipos y Suministros/provisión & distribución , Distrofia Endotelial de Fuchs/tratamiento farmacológico , Terapia Genética/métodos , Humanos , Soluciones Oftálmicas/administración & dosificación , Presbiopía/tratamiento farmacológico , Enfermedades de la Retina/tratamiento farmacológico , Estados Unidos , United States Food and Drug AdministrationAsunto(s)
Tratamiento Farmacológico de COVID-19 , Vacunas contra la COVID-19 , Industria Farmacéutica/economía , Medicamentos Genéricos/economía , Medicamentos Genéricos/provisión & distribución , Concesión de Licencias , Patentes como Asunto , COVID-19/economía , Vacunas contra la COVID-19/economía , Vacunas contra la COVID-19/provisión & distribución , Desarrollo de Medicamentos/economía , Humanos , Concesión de Licencias/legislación & jurisprudencia , Patentes como Asunto/legislación & jurisprudencia , Organización Mundial de la Salud/organización & administraciónRESUMEN
Health officials and scientists have warned that we face the threat of a potentially devastating influenza pandemic. Instead, we are now in the midst of a global coronavirus (COVID-19) pandemic. National and international pandemic preparedness plans have focused on developing vaccines and antiviral treatments. Another way to confront the COVID-19 pandemic (and future pandemics) might be to treat patients with inexpensive and widely available generic drugs that target the host response to infection, not the virus itself. The feasibility of this idea was tested during the Ebola outbreak in West Africa in 2014. This experience should inform our approach to treating COVID-19 patients. It could also save lives during outbreaks of other emerging infectious diseases and episodes of everyday acute critical illness. If this "bottom up" syndromic approach to treating acute critical illness were shown to be effective, it could have a dramatic impact on health, equity and security throughout the world. HIGHLIGHTS: Uncertainty about the outcome of COVID-19 is driving the social, economic and political distress associated with the pandemic. Treating the host response to COVID-19 with inexpensive and widely available generic drugs might save lives and mitigate this distress. Undertaking research on this idea will require political leadership.
Asunto(s)
Antivirales/uso terapéutico , Tratamiento Farmacológico de COVID-19 , Medicamentos Genéricos/uso terapéutico , Liderazgo , Neumonía Viral/tratamiento farmacológico , Política , Antivirales/provisión & distribución , Investigación Biomédica , COVID-19/epidemiología , Vacunas contra la COVID-19 , Medicamentos Genéricos/provisión & distribución , Humanos , Pandemias , Neumonía Viral/epidemiología , Neumonía Viral/virología , SARS-CoV-2RESUMEN
BACKGROUND: To monitor the magnitude of the drug shortage problem in Canada, since 2017, Health Canada has required manufacturers to report drug shortages. This study aimed to identify the factors associated with drug shortages in Canada. METHODS: We conducted a retrospective cohort study of all prescription drugs available on the market between Mar. 14, 2017, and Sept. 12, 2018, in Canada. All drugs of the same active ingredient, dosage form, route of administration and strength were grouped into a "market." Our main outcome was shortages at the market level, determined using the Drug Shortages Canada database. We used logistic regression to identify associated factors such as market structure, route or dosage form, and Anatomic Therapeutic Chemical (ATC) classification. RESULTS: Among the 3470 markets included in our analysis, 13.3% were reported to be in shortage. Markets with a single generic manufacturer were more likely to be in shortage than other markets. Markets with oral nonsolid route or dosage form were more likely to be in shortage than those that were oral solid with regular release (odds ratio [OR] 1.66, 95% confidence interval [CI] 1.11 to 2.49). Markets for sensory organs were more likely to be in shortage than most other ATC classes. Markets with a higher proportion of drugs covered by public insurance programs were more likely to be in shortage (OR 1.03, 95% CI 1.00 to 1.05 per 10% increase). INTERPRETATION: Markets with a single generic manufacturer were most likely to be in shortage. To ensure the security of drug supply, governments should be vigilant in monitoring markets with a single generic manufacturer, with complex manufacturing processes, with higher demand from public programs or those that are in certain ATC classes.
Asunto(s)
Industria Farmacéutica/organización & administración , Medicamentos Genéricos/provisión & distribución , Mercadotecnía/métodos , Medicamentos bajo Prescripción/provisión & distribución , Canadá , Bases de Datos Farmacéuticas , Formas de Dosificación , Vías de Administración de Medicamentos , Sector de Atención de Salud , Humanos , Seguro de Servicios Farmacéuticos , Modelos Logísticos , Estudios RetrospectivosAsunto(s)
Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/epidemiología , Concesión de Licencias/legislación & jurisprudencia , Patentes como Asunto/legislación & jurisprudencia , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/epidemiología , COVID-19 , Países en Desarrollo , Industria Farmacéutica/legislación & jurisprudencia , Medicamentos Genéricos/economía , Medicamentos Genéricos/provisión & distribución , Accesibilidad a los Servicios de Salud/economía , Humanos , PandemiasRESUMEN
While the world is facing the urgency of the COVID-19 pandemic, policymakers must plan for the direct response to the outbreak while minimising its collateral impact. Maintaining the supply chain of pharmaceutical products is not only paramount to cover the immediate medical response but will be fundamental to reducing disruption of the healthcare delivery system, which requires constant medicines, diagnostic tools and vaccines for smooth functioning. In this equation, the role of the Indian pharmaceutical industry will not only be critical to meet the domestic need of over 1.3 billion inhabitants but will equally be important for the rest of the world, including wealthy economies. Preventing a significant disruption of the Indian pharmaceutical supply chain during the outbreak and preparing it for large scale production for COVID-19 therapeutic or preventive medical products will not only help India but will assist the global response to this outbreak.
Asunto(s)
Infecciones por Coronavirus , Medicamentos Genéricos/provisión & distribución , Pandemias , Preparaciones Farmacéuticas/provisión & distribución , Neumonía Viral , Betacoronavirus , COVID-19 , Comercio , Industria Farmacéutica , Humanos , India , SARS-CoV-2RESUMEN
A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry.
Asunto(s)
Industria Farmacéutica/legislación & jurisprudencia , Medicamentos Genéricos/economía , Patentes como Asunto , Industria Farmacéutica/economía , Medicamentos Genéricos/provisión & distribución , Humanos , Estados UnidosRESUMEN
Background Access to medicines is important for long-term care of cardiovascular diseases and hypertension. This study provides a cross-country assessment of availability, prices, and affordability of cardiovascular disease and hypertension medicines to identify areas for improvement in access to medication treatment. Methods and Results We used the World Health Organization online repository of national essential medicines lists (EMLs) for 53 countries to transcribe the information on the inclusion of 12 cardiovascular disease/hypertension medications within each country's essential medicines list. Data on availability, price, and affordability were obtained from 84 surveys in 59 countries that used the World Health Organization's Health Action International survey methodology. We summarized and compared the indicators across lowest-price generic and originator brand medicines in the public and private sectors and by country income groups. The average availability of the select medications was 54% in low- and lower-middle-income countries and 60% in high- and upper-middle-income countries, and was higher for generic (61%) than brand medicines (41%). The average patient median price ratio was 80.3 for brand and 16.7 for generic medicines and was higher for patients in low- and lower-middle-income countries compared with high- and upper-middle-income countries across all medicine categories. The costs of 1 month's antihypertensive medications were, on average, 6.0 days' wage for brand medicine and 1.8 days' wage for generics. Affordability was lower in low- and lower-middle-income countries than high- and upper-middle-income countries for both brand and generic medications. Conclusions The availability and accessibility of pharmaceuticals is an ongoing challenge for health systems. Low availability and high costs are major barriers to the use of and adherence to essential cardiovascular disease and antihypertensive medications worldwide, particularly in low- and lower-middle-income countries.